Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Novartis drops asthma drug fevipiprant after trial failures

ZURICH (Reuters) - Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.


The drug’s star fell in October when the Basel-based company announced it had failed a pair of trials in moderate asthmatic patients.

Now, fevipiprant has flopped in two additional studies in moderate-to-severe patients, spelling the end to its development for asthma.

Novartis chief drug developer John Tsai had continued to hold out hope that the trial failures in moderate patients were a fluke and that the drug would be more effective in patients hit harder by the respiratory disorder.

Instead, fevipiprant failed to reduce exacerbations — an acute episode of symptoms growing worse — compared to a placebo over a 52-week treatment period for either the 150 mg or 450 mg dose of the drug.

“The totality of these results do not support further development of fevipiprant in asthma,” said Novartis, which had hoped the medicine would become an alternative for patients for whom existing therapies like inhaled corticosteroids did not bring sufficient improvement.

Despite the failure, Novartis continues to hold out hope that it has about two dozen potential blockbuster medicines — those that will exceed $1 billion in annual sales — in its pipeline.

DECEMBER 16, 2019


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies